Literature DB >> 25098542

Brain fluorodeoxyglucose PET in adrenoleukodystrophy.

Ettore Salsano1, Giorgio Marotta2, Valentina Manfredi2, Anna Rita Giovagnoli2, Laura Farina2, Mario Savoiardo2, Davide Pareyson2, Riccardo Benti2, Graziella Uziel2.   

Abstract

OBJECTIVE: To investigate the cerebral glucose metabolism in subjects with X-linked adrenoleukodystrophy (X-ALD) by using brain [(18)F]-fluorodeoxyglucose PET (FDG-PET).
METHODS: Cross-sectional study in which 12 adults with various forms of X-ALD underwent clinical evaluation and brain MRI, followed by brain FDG-PET, neuropsychological assessment, and personality and psychopathology evaluation using the Symptom Checkist-90-Revised (SCL-90-R) and the Millon Clinical Multiaxial Inventory-III (MCMI-III).
RESULTS: When compared to healthy control subjects (n = 27) by using Statistical Parametric Mapping 8 software, the patients with X-ALD-with or without brain MRI changes-showed a pattern of increased glucose metabolism in frontal lobes and reduced glucose metabolism in cerebellum and temporal lobe areas. On single case analysis by Scenium software, we found a similar pattern, with significant (p < 0.02) correlation between the degree of hypermetabolism in the frontal lobes of each patient and the corresponding X-ALD clinical scores. With respect to personality, we found that patients with X-ALD usually present with an obsessive-compulsive personality disorder on the MCMI-III, with significant (p < 0.05) correlation between glucose uptake in ventral striatum and severity of score on the obsessive-compulsive subscale.
CONCLUSIONS: We examined cerebral glucose metabolism using FDG-PET in a cohort of patients with X-ALD and provided definite evidence that in X-ALD the analysis of brain glucose metabolism reveals abnormalities independent from morphologic and signal changes detected by MRI and related to clinical severity. Brain FDG-PET may be a useful neuroimaging technique for the characterization of X-ALD and possibly other leukodystrophies.
© 2014 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25098542     DOI: 10.1212/WNL.0000000000000770

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

Review 1.  Blood brain barrier: An overview on strategies in drug delivery, realistic in vitro modeling and in vivo live tracking.

Authors:  Pawan Kumar Pandey; Ashok Kumar Sharma; Umesh Gupta
Journal:  Tissue Barriers       Date:  2015-12-15

2.  Application of siemens SMART neuro attenuation correction in brain PET imaging.

Authors:  Xiaonan Shao; Mei Xu; Chun Qiu; Rong Niu; Yuetao Wang; Xiaosong Wang
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

3.  Late adult-onset adrenomyeloneuropathy evolving with atypical severe frontal lobe syndrome: Importance of neuroimaging.

Authors:  Clemente Dato; Guglielmo Capaldo; Chiara Terracciano; Filomena Napolitano; Alessandra D'Amico; Sabina Pappatà; Filippo Maria Santorelli; Giuseppe Di Iorio; Simone Sampaolo; Mariarosa Ab Melone
Journal:  Radiol Case Rep       Date:  2018-12-05

4.  Glucose metabolism in the brain in LMNB1-related autosomal dominant leukodystrophy.

Authors:  Johannes Finnsson; Mark Lubberink; Irina Savitcheva; David Fällmar; Atle Melberg; Eva Kumlien; Raili Raininko
Journal:  Acta Neurol Scand       Date:  2018-09-25       Impact factor: 3.209

Review 5.  Heterogeneity of Neuroinflammatory Responses in Amyotrophic Lateral Sclerosis: A Challenge or an Opportunity?

Authors:  Giada Cipollina; Arash Davari Serej; Gianluca Di Nolfi; Andrea Gazzano; Andrea Marsala; Mauro G Spatafora; Marco Peviani
Journal:  Int J Mol Sci       Date:  2020-10-25       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.